Cryo Cell International (CCEL) Q2 2024 earnings summary

Executive summary

• Revenue for the six months ended May 31, 2024 increased 2% to $15.9 million, driven by a 4% rise in processing and storage fees and a 1% increase in new domestic cord blood specimens processed year-over-year.

• Fiscal Q2 2024 revenue rose 3% year-over-year to $8.0 million, driven by higher processing and storage fees.

• Net income for the six months was $1.2 million, up from $988,000 in the prior year period, with EPS of $0.15 basic and diluted, compared to $0.12 last year.

• Net income increased to $656,000 ($0.08 per share) in Q2 from $221,000 ($0.03 per share) year-over-year.

• The company continues to invest in R&D, including funding for the Duke IMPACT Study and the development of a new facility in North Carolina, which received its certificate of occupancy in May 2024.

Financial highlights

• Total revenue for Q2 2024 was $8.0 million, up 3% from $7.8 million in Q2 2023, with a 5% increase in processing and storage fees.

• Processing and storage fee revenue reached $7.97 million, up from $7.58 million year-over-year.

• Cost of sales for the six months was $4.2 million, down 1% year-over-year, with gross margin improvement.

• Cost of sales decreased by 6% and R&D expenses declined to $241,000 from $305,000 year-over-year.

• Selling, general and administrative expenses rose 6% to $8.4 million for the six months, reflecting higher personnel and professional fees.

• Operating income for the six months was $2.2 million, down from $2.7 million in the prior year.

• Interest expense decreased to $586,000 from $936,000 year-over-year, aided by the termination of an interest rate swap.

• Cash and cash equivalents at May 31, 2024 were $469,000, up from $406,000 at November 30, 2023.

Outlook and guidance

• Management anticipates sufficient liquidity for at least the next 12 months, with plans for $5 million in discretionary capital expenditures for property buildout, equipment, and clinical trial funding.

• The company expects to open the Cryo-Cell Institute for Cellular Therapies and begin infusing patients in Q4 2024, pending FDA approval for its Phase 3 CP Trial.

• Over $50 million in capital is projected to be needed over the next five years for clinical trials, manufacturing, and expansion initiatives.

• Forward-looking statements highlight plans for global expansion, product diversification, and biopharmaceutical manufacturing.

• Ongoing transformation into a vertically integrated cellular therapy company, leveraging Duke University partnership.